PLUS THERAPEUTICS, INC.
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
PSTV | NDAQ
Overview
Corporate Details
- ISIN(s):
- US23283K2042 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 4200 MARATHON BLVD., 78756 AUSTIN
- Website:
- http://www.plustherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for PLUS THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
